TVRD · Tvardi Therapeutics, Inc. · Metrics
$1.05
+0.06 (+5.84%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, the Company has concluded that management's plans do not alleviate substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$13.87M
Shares
13.34M
Volume · Oct 21
87.41K
Avg daily vol (3M)
258.15K
TVRD metrics
70 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$0.99
Market cap
$13.87M
Price action
20 metricsPrice change (1W)
-4.6%
Price change (30D)
-38.4%
Price change (3M)
-65.3%
Price change (6M)
-68.6%
Price change (YTD)
-76.9%
Price change (1Y)
-83.9%
Trailing year
Price change (5Y)
—
52-week high
$6.17
52-week low
$0.97
Change from 52-week high
-83.9%
Change from 52-week low
+2.3%
Annualized volatility
120.5%
Annualized volatility (3M)
84.4%
Beta
1.1
RSI (14D)
31.7
Price vs SMA 50
-35.1%
Price vs SMA 200
-65.7%
Avg volume (3M)
258,149
Relative volume
0.8
Average dollar volume
$484,646
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
13.34M
Valuation
12 metricsP / E (TTM)
24.8
Trailing earnings · reciprocal yield 4.0%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.8×
reciprocal yield 56.2%
P / book
1.6
reciprocal yield 62.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-193.5%
Historical valuation
8 metricsP / E historical average (3Y)
184.2×
reciprocal yield 0.5%
P / E historical average (5Y)
184.2×
reciprocal yield 0.5%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-19
Profitability
9 metricsGross margin
—
Operating margin
-393.8%
Trailing 12 months
Net margin
-411.9%
Gross profit (TTM)
—
Operating profit (TTM)
−$27.20M
Net income (TTM)
−$26.06M
Trailing 12 months
Diluted EPS (TTM)
$0.04
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+20.3%
Year over year
Net income growth YoY
-255.0%
Revenue (TTM)
$7.57M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+11.0%
Year over year · more shares
Revenue CAGR (3Y)
-32.3%
Revenue CAGR (5Y)
-18.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-310.9%
Return on assets
-148.8%
Debt / equity
0.0
Current ratio
1.9
EBITDA (TTM)
−$27.11M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$15.77M
Latest balance sheet
Cash & equivalents
$15.77M
Total assets
$17.52M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$25.03M
Capital expenditures (TTM)
$1.05M
R&D (TTM)
$18.01M
SG&A (TTM)
—
Stock compensation (TTM)
$1.40M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
57
13F filer change QoQ
-10
Institutional ownership
16.7%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
11.0%
Private-fund adviser ownership
10.5%
Active holders' share change QoQ
+3.2%
Holder tenure
3.9
Price vs estimated holder cost
-76.1%
Ownership (registered funds)
1 metricsIndex-fund ownership
4.2%
Short interest
3 metricsShort interest
1.7%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
32 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged